康辰药业(603590.SH)：KC1036 联合 PD-1 抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌Ⅱ期临床研究完成首例受试者入组

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has successfully completed the first patient enrollment for the clinical trial of KC1036 in combination with PD-1 antibody and platinum-based chemotherapy for the first-line treatment of advanced recurrent or metastatic esophageal squamous cell carcinoma [1] Group 1: Product Development - KC1036 is a class 1 innovative drug independently developed by the company, with global intellectual property rights [1] - The drug exerts anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL, demonstrating strong vascular targeting of VEGFR and inhibiting tumor cell growth [1] - By inhibiting AXL, KC1036 can enhance the host's anti-tumor immune response, thereby preventing immune evasion by tumors [1] Group 2: Clinical Research - Clinical studies for KC1036 are currently being conducted for multiple indications, including gastrointestinal tumors, thymic tumors, and pediatric Ewing sarcoma [1] - To date, over 300 subjects have been enrolled in the clinical studies for KC1036, with existing results showing outstanding anti-tumor activity, as well as good safety and tolerability [1]